Rebamipide: Uses and Mechanism of Action
Mechanism of Action
Rebamipide is a mucoprotective agent with multiple mechanisms: it induces prostaglandin synthesis, scavenges free oxygen radicals, enhances mucin production, and inhibits NLRP3 inflammasome activation. 1, 2
The drug's protective effects stem from:
- Prostaglandin induction - stimulates endogenous protective prostaglandins in the gastric mucosa
- Free radical scavenging - eliminates reactive oxygen species that damage mucosal cells
- Mucin enhancement - increases the protective mucus layer coating the gastrointestinal tract
- Anti-inflammatory action - recently discovered to disrupt NLRP3-NEK7 inflammasome interaction 3
Clinical Uses
Established Gastrointestinal Indications 1, 4
Rebamipide is approved and widely used in Asia and Russia for:
- Gastric ulcers - demonstrates efficacy superior to pantoprazole, sucralfate, misoprostol, famotidine, lansoprazole, and esomeprazole 1
- Chronic gastritis with hyperacidity (acute stage)
- Erosive gastritis
- NSAID-induced gastropathy prevention - comparable efficacy to misoprostol but with significantly better tolerability and lower withdrawal rates (10.3% vs 18.6%, p=0.0103) 5, 6
- Helicobacter pylori eradication support
- Gastroesophageal reflux disease (GERD)
Emerging and Experimental Uses
Radiation-induced proctopathy: Listed as an experimental treatment option in recent guidelines, though noted as not available in the UK 7, 8. Used as enema therapy for radiation-induced rectal bleeding, though data remain limited to case series 8.
Other conditions under investigation 4, 9:
- Ulcerative colitis and pouchitis
- NSAID enteropathy
- Rheumatologic conditions (gouty arthritis, rheumatoid arthritis, osteoarthritis, Sjögren's syndrome)
- Ophthalmology (corneal epithelium regeneration, dry eye)
- Oncology (oral mucositis after chemoradiotherapy)
- Bone regeneration in traumatology
- Neuroinflammatory diseases (Parkinson's disease via NLRP3 inhibition) 3
Key Clinical Considerations
Rebamipide offers a favorable safety profile with mild side effects and low adverse event rates, contributing to its widespread adoption across Southeast Asia 1. For NSAID-induced gastropathy prevention, rebamipide reduces gastrointestinal symptom severity significantly more than misoprostol (p=0.0002) and requires less antacid use (p=0.0258) 5.
The drug's efficacy in preventing NSAID-induced mucosal breaks is comparable to standard PPIs (RR 1.00,95% CI 0.51-1.95), making it a viable alternative for patients with contraindications to long-term PPI therapy 6.
Important caveat: Despite promising mechanisms and clinical data from Asia, rebamipide remains unavailable in many Western countries including the UK and US 7, 8. The FDA drug label information provided in the evidence actually describes ramipril (an ACE inhibitor), not rebamipide - this appears to be a data error 10.